Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 73.28% is 83% above its 5-year average of 40.03%, around the middle of its 5-year range (-4.11%–162.01%).
10.11% below its 12-month average of 81.52%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 85.82%.
GROSS MARGIN
73.28%
GROSS MARGIN AVG TTM
81.52%
GROSS MARGIN AVG 3Y
50.82%
GROSS MARGIN AVG 5Y
40.03%
GROSS MARGIN AVG 10Y
30.08%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-10.11%
CURRENT VS 3Y AVG
+44.19%
CURRENT VS 5Y AVG
+83.07%
CURRENT VS 10Y AVG
+143.63%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+77.09%
vs the sector median at left
Aclaris Therapeutics, Inc.
Market Cap
$520.25M
Gross Margin
73.28%
TTM Avg
81.52%
3Y Avg
50.82%
5Y Avg
40.03%
Market Cap
$520.22M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
31.77%
Market Cap
$523.79M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$520.84M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$511.66M
Gross Margin
100.00%
TTM Avg
50.00%
3Y Avg
75.00%
5Y Avg
83.33%
Market Cap
$510.29M
Gross Margin
49.79%
TTM Avg
48.93%
3Y Avg
50.95%
5Y Avg
52.39%
Market Cap
$533.38M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$507.38M
Gross Margin
0.00%
TTM Avg
50.00%
3Y Avg
-2215.86%
5Y Avg
-1460.58%
Market Cap
$535.16M
Gross Margin
82.92%
TTM Avg
86.33%
3Y Avg
62.04%
5Y Avg
41.36%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | $520.25M | 73.28% | 81.52% | 50.82% | 40.03% |
| Altimmune, Inc. (ALT)vs › | $520.22M | 100.00% | 100.00% | 100.00% | 31.77% |
| Immix Biopharma, Inc. (IMMX)vs › | $523.79M | 0.00% | 0.00% | 0.00% | 0.00% |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $520.84M | 0.00% | 0.00% | 0.00% | 0.00% |
| Crescent Biopharma, Inc. (CBIO)vs › | $511.66M | 100.00% | 50.00% | 75.00% | 83.33% |
| 908 Devices Inc. (MASS)vs › | $510.29M | 49.79% | 48.93% | 50.95% | 52.39% |
| Nuvectis Pharma, Inc. (NVCT)vs › | $533.38M | 0.00% | 0.00% | 0.00% | 0.00% |
| Allogene Therapeutics, Inc. (ALLO)vs › | $507.38M | 0.00% | 50.00% | -2215.86% | -1460.58% |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $535.16M | 82.92% | 86.33% | 62.04% | 41.36% |
| Delcath Systems, Inc. (DCTH)vs › | $535.09M | 87.05% | 84.77% | 78.39% | 75.97% |
Gross Margin
73.3%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 85.82% |
| 2026-03-31 | 80.21% |
| 2025-12-31 | 162.01% |
| 2025-09-30 | 83.69% |
| 2025-06-30 | -4.11% |
| 2025-03-31 | 65.22% |
| 2024-12-31 | -0.98% |
| 2024-09-30 | 44.59% |
| 2024-06-30 | 30.98% |
| 2024-03-31 | 23.27% |
| 2023-12-31 | 63.41% |
| 2023-09-30 | 11.74% |
| 2023-06-30 | 14.82% |
| 2023-03-31 | 26.07% |
| 2022-12-31 | 80.47% |
| 2022-09-30 | 56.76% |
| 2022-06-30 | 30.10% |
| 2022-03-31 | 20.51% |
| 2021-12-31 | 23.45% |
| 2021-09-30 | 33.76% |
| 2021-06-30 | 30.76% |
| 2021-03-31 | 32.36% |
| 2020-12-31 | 18.61% |
| 2020-09-30 | 17.94% |
| 2020-06-30 | 32.11% |
| 2020-03-31 | 9.81% |
| 2019-12-31 | 6.21% |
| 2019-09-30 | 15.97% |
| 2019-06-30 | 53.91% |
| 2019-03-31 | 44.91% |
| 2018-12-31 | 4.36% |
| 2018-09-30 | 26.72% |
| 2018-06-30 | 67.87% |
| 2018-03-31 | 13.51% |
| 2017-12-31 | 24.52% |
| 2017-09-30 | 33.77% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 0.00% |
| 2015-09-30 | 0.00% |
| 2015-06-30 | 0.00% |
| 2015-03-31 | 0.00% |
| 2014-12-31 | 0.00% |
| 2014-09-30 | 0.00% |
| 2014-06-30 | 0.00% |
| 2014-03-31 | 0.00% |
